Please ensure Javascript is enabled for purposes of website accessibility

Why Karmon's "Positive" Data Turned Into a 21% Decline

By Brian Orelli, PhD – Feb 13, 2018 at 7:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sometimes the devil is in the details.

What happened

Kadmon (KDMN) closed down more than 21% today after announcing phase 2 data for its drug candidate KD025 in patients with a lung disease called idiopathic pulmonary fibrosis (IPF). While the company called the data "positive," investors saw that it offered more questions than answers.

So what

First, the good news: The forced vital capacity (FVC), a measure of lung function, decreased by a median of 48 mL after 24 weeks of treatment with KD025, compared to a median of 175 mL for patients given best supportive care. Looking at the drug-treated patients another way, they went from a decrease of 126 mL in the year before being treated to an annualized rate of 32 mL after being treated.

All that looks good, but FVC is usually presented as a percent predicted number because height, age, sex, and race can affect FVC values. When calculating the FVC on a percent predicted basis, the difference wasn't as impressive with patients taking KD025 having a median decline of 1% while the control group dropped 2%.

The decline in FVC percent predicted is half as much for patients treated with KD025, but the values aren't numerically all that different, which is worrisome given the small number of evaluable patients -- 20 for the treated arm and nine for the control arm.

Adding to the worry about the patient numbers, seven patients treated with KD025 dropped out due to adverse events. Only one was deemed due to treatment, but the high dropout rate is concerning, especially since the Food and Drug Administration will likely require data from patients who drop out to be included in the overall results.

A doctor showing a patient her chest X-ray while she's lying in a hospital bed.

Image source: Getty Images.

Now what

Kadmon is looking to run a larger trial with 150 patients as well as another phase 2 trial testing KD025 in combination with other drugs used to treat IPF. While it's hard to draw any firm conclusions over whether those trials will be successful based on these phase 2 data, it looks like KD025 has enough activity to justify developing it further.

Shares of Kadmon ran up going into the data release, so even after the massive slide, today's closing price is actually slightly higher than where it started the year, which seems about right given the data.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Kadmon Holdings, Inc. Stock Quote
Kadmon Holdings, Inc.
KDMN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.